Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk..
Angiology. 63(1), 9-11.
(2012). Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome..
Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
(2012). Nicotinic Acid and new-onset diabetes..
Horm Metab Res. 47(7), 544-5.
(2015). Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental?.
Atherosclerosis. 211(1), 9-14.
(2010). Gene Polymorphisms in Cardiovascular Disease and Cancer..
Angiology. 69(8), 738-739.
(2018). Lipids, Statins and Heart Failure: An Update..
Curr Pharm Des. 22(31), 4796-4806.
(2016). Statins and Type 2 Diabetes Mellitus: An Update After 1 Year..
Curr Pharm Des. 22(18), 2723-5.
(2016). Vitamin D deficiency, statin-related myopathy and other links with vascular risk..
Curr Med Res Opin. 27(9), 1691-2.
(2011). Metabolic syndrome and non-cardiac vascular diseases: an update from human studies..
Curr Pharm Des. 20(31), 4944-52.
(2014). Fibrinogen, hematocrit, and platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study..
Clin Appl Thromb Hemost. 18(1), 113-4.
(2012). Reaching hypertriglyceridemia goals..
Curr Med Res Opin. 30(3), 391-3.
(2014). Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial..
J Hepatol. 57(2), 476.
(2012). Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview..
Curr Vasc Pharmacol. 12(4), 627-41.
(2014). Achieving lipid targets in primary care settings..
Curr Med Res Opin. 30(10), 1971-4.
(2014). Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance..
J Clin Lipidol. 6(1), 93.
(2012). Should we expand the concept of coronary heart disease equivalents?.
Curr Opin Cardiol. 29(4), 389-95.
(2014). Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia..
Int Angiol. 30(3), 295; author reply 296.
(2011). New developments in the treatment and prevention of vascular disease--part 1..
Curr Pharm Des. 16(34), 3767-9.
(2010). High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality?.
Curr Med Chem. 21(25), 2917-26.
(2014). Passive smoking: the democratic right of nonsmokers to survive..
Angiology. 62(7), 520-2.
(2011). The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome..
Drugs. 69(11), 1417-31.
(2009). Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit..
Expert Rev Cardiovasc Ther. 12(3), 295-6.
(2014). Current treatment for nonalcoholic fatty liver disease..
Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
(2011). The role of statins in the treatment of type 2 diabetes mellitus: an update..
Curr Pharm Des. 20(22), 3665-74.
(2014).
(2011).